Topoisomerase IV · PROTEIN COMPLEX · Bacteria
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Topoisomerase IV shows approved-linked disease relevance led by bacterial disease. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P0AFI2. Start with bacterial disease, then reuse UniProt P0AFI2 as the stable protein anchor across project notes and exports.
Start with bacterial disease, then reuse UniProt P0AFI2 as the stable protein anchor across project notes and exports.
Topoisomerase IV shows approved-linked disease relevance led by bacterial disease. 5 more disease programs remain visible in the same review block. 11 linked drugs remain visible in the same block.
Start review with bacterial disease because it currently carries approved-linked support. Linked drugs include ALATROFLOXACIN MESYLATE, CIPROFLOXACIN, GEPOTIDACIN, NEMONOXACIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyDNA topoisomerase 4 subunit A
Review this target as Topoisomerase IV, mapped to UniProt P0AFI2. ChEMBL maps the protein component as DNA topoisomerase 4 subunit A. Sequence length is 752 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Topoisomerase IV as ChEMBL target CHEMBL2363076, mapped to UniProt P0AFI2. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Topoisomerase IV is the right protein anchor across sources, using UniProt P0AFI2 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why bacterial disease is currently framed as approved-linked support. It currently carries 11 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Topoisomerase IV |
| Target Type | PROTEIN COMPLEX |
| Organism | Bacteria |
| UniProt | P0AFI2 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | DNA topoisomerase 4 subunit A |
| UniProt Accession | P0AFI2 |
| Component Type | Protein |
| Sequence Length | 752 aa |
DNA topoisomerase 4 subunit A
Review this target as Topoisomerase IV, mapped to UniProt P0AFI2. ChEMBL maps the protein component as DNA topoisomerase 4 subunit A. Sequence length is 752 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Topoisomerase IV shows approved-linked disease relevance led by bacterial disease. 5 more disease programs remain visible in the same review block.
Start review with bacterial disease because it currently carries approved-linked support. Linked drugs include ALATROFLOXACIN MESYLATE, CIPROFLOXACIN, GEPOTIDACIN, NEMONOXACIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.